Psychiatric and Psychological Interventions for Depression in Patients With Heart Disease: A Scoping Review

Abstract

Depression in patients with cardiovascular disease is independently associated with progression of heart disease, major adverse cardiac events, and mortality. A wide variety of depression treatment strategies have been studied in randomized controlled trials as the field works to identify optimal depression treatments in this population. A contemporary scoping review of the literature can help to consolidate and synthesize the growing and disparate literature on depression treatment trials in people with cardiovascular disease. We conducted a scoping review utilizing a systematic search of the literature via 4 databases (PubMed, PsycINFO, EMBASE, and Google Scholar) from database inception to March 2020. We identified 42 relevant randomized controlled trials of depression treatment interventions in patients with cardiac disease (n=9181 patients with coronary artery disease, n=1981 patients with heart failure). Selective serotonin reuptake inhibitors appear to be safe in patients with cardiac disease and to have beneficial effects on depression (and some suggestion of cardiac benefit) in patients with coronary artery disease, with less evidence of their efficacy in heart failure. In contrast, psychotherapy appears to be effective for depression in coronary artery disease and heart failure, but with less evidence of cardiac benefit. Newer multimodal depression care management approaches that utilize flexible approaches to patients' care have been less studied but appear promising across cardiac patient groups. Selective serotonin reuptake inhibitors may be preferred in the treatment of patients with coronary artery disease, psychotherapy may be preferred in heart failure, and more flexible depression care management approaches have shown promise by potentially using both approaches based on patient needs.

Association of Major Depressive Disorder on Heart Failure With Reduced and Preserved Ejection Fraction: Analysis of National Readmission Database 2018

“…This difference could be related to the study's inclusion of all types of heart failure but not specific HFrEF and HFpEF ICD codes. The current expert recommendations for depression in HF patients are similar to non-HF patients however, antidepressant efficacy has not been demonstrated yet in the HF patients but the more effective therapies are psychotherapy and care management [22]. This is unfortunately not measurable in our study due to the inherent limitation of the database itself.…”

Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis

“…Serotonin reuptake inhibitors (SRIs), including selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are the most widely prescribed antidepressants that are used in various psychiatric settings including cardiac patients [ 1 ]. With respect to the favourable safety profiles compared to older generations of antidepressants, SRI antidepressants and antithrombotic agents (anticoagulants and antiplatelet) are often prescribed together as depression and anxiety often coexist with cardiovascular/cerebrovascular diseases, atrial fibrillation, myocardial infarction, and other thromboembolic disorders [ 2 , 3 ].…”

A phone and text message intervention to improve physical activity in midlife: initial feasibility testing

“…Likewise, participants showed substantial improvements in psychological factors such as positive affect and depression during the intervention. Improvements in these domains have the potential to improve quality of life, promote greater engagement in physical activity, and boost overall health, given the literature prospectively connecting improvements in these factors with greater participation in physical activity and superior health outcomes (Levine et al, 2021 ; Zambrano et al, 2020b ). Indeed, in this study, participants moved from being a mean of 45 min below recommended weekly MVPA completion of 150 min per week (105 min/week at baseline on accelerometer) to exceeding this benchmark (mean of approximately 155 min/week, based on improvement by 7.2 min per day) by study end.…”